A laboratory runs an LC-MS check on a peptide that its HPLC report describes as 98.6 percent pure. The chromatogram shows one tall, fairly symmetrical main peak. But when the analyst extracts mass spectra from the front half and the back half of that peak, they are not quite the same: the trailing edge carries a second species about one dalton heavier than the target. Nothing on the UV trace hinted at it. The main peak was two compounds all along.
This is co-elution, and it is the most important limitation of chromatographic purity because it is both common and flattering. The sections below explain why it happens with peptides in particular, why it always biases the result in the same direction, and how laboratories find it.
Why close relatives travel together
Reverse-phase HPLC separates molecules according to how strongly they partition into the hydrophobic stationary phase. It is a broad sorting mechanism. Molecules with similar overall hydrophobicity move through the column at similar speeds, and when the difference in their retention is smaller than the width of a peak, the detector records a single band.
The molecules most similar to a peptide are its own synthesis byproducts and degradation products, which are exactly the species a purity test exists to find. Typical examples include:
- a deletion sequence missing one residue, especially a residue that contributes little to hydrophobicity;
- a deamidated form, in which an asparagine or glutamine side chain has been converted to an acid;
- a diastereomer, where racemization during synthesis has inverted one residue’s configuration;
- an isoaspartate rearrangement, which changes the backbone linkage without changing the mass.
Any of these can elute within a few seconds of the parent. Peptide synthesis impurities describes where each type comes from.
The bias only runs one way
Area percentage purity is the main peak’s area divided by the total. The calculation assumes each peak is one compound. If an impurity sits under the main peak, its area is counted as main peak area, and the purity figure rises. A sample that is really 95 percent target, carrying 3 percent of a co-eluting impurity and 2 percent of resolved impurities, will be reported at 98 percent. The chromatogram looks ordinary and the integration software has no way to know.
Because the error never lowers the figure, a method that resolves more impurities will often report a lower purity than one that resolves fewer. The lower number can be the more accurate one. This is also why a purity percentage on its own is a weaker statement than the chromatogram behind it: a trace can be inspected for shoulders and asymmetry, while a number cannot. The basics of that inspection are in how to read an HPLC chromatogram.
Ways to detect a shared peak
The available checks range from free to demanding, and each has blind spots.
| Check | What it looks for | What it can miss |
|---|---|---|
| Peak shape inspection | Shoulders, unexpected width, fronting or tailing without another explanation | A minor component centered almost exactly under the main peak |
| Diode-array peak purity | Differences between UV spectra collected across the peak | Any impurity with the same UV spectrum as the parent, such as a diastereomer or isoaspartate form |
| Orthogonal separation | A second method with different selectivity: another stationary phase, another pH, or ion exchange | Pairs that happen to co-elute under both mechanisms, which is uncommon |
| LC-MS across the peak | Different masses at different points in the peak | Species with identical mass, such as diastereomers and isoaspartate forms |
Two points deserve emphasis. First, a diode-array detector compares spectra; if two species share a chromophore, it cannot separate them, so a “pass” on spectral peak purity is only strong evidence when the likely impurities absorb differently. Second, mass spectrometry distinguishes by mass, so it cannot tell apart isomers. For same-mass, same-spectrum impurities, the decisive test is a separation with different selectivity. For deamidation, the one-dalton shift is detectable by mass spectrometry but sits close to the parent’s isotope peaks, so it needs careful interpretation. More on the identity side is in mass spectrometry and peptide identity.
How method design limits the problem
Well-developed methods address co-elution before routine use. Developers identify a critical pair, usually the main peak and its nearest known impurity, and set a minimum resolution between them as part of system suitability. Gradients are often made shallower around the main peak to spread closely related species apart. Choice of mobile phase additive and column chemistry also shifts selectivity. None of this guarantees that every possible impurity is resolved, but it makes the method’s limits explicit.
Column temperature is another lever that is easy to overlook. Raising or lowering it changes retention for different peptides by different amounts, so a pair that merges at one temperature may separate at another. Developers who screen two or three temperatures alongside two column chemistries often find a combination that splits a stubborn pair. The corollary for anyone reading a report is that small, undocumented changes to these settings can change which impurities are visible.
Questions worth asking a testing laboratory
- May we see the chromatogram, not only the percentage?
- What wavelength was used for detection?
- Was spectral peak purity evaluated, and against what threshold?
- Is there a defined critical pair and a resolution requirement?
- Has the result ever been compared with an orthogonal method?
Even a clear answer has limits. Finding that a peak is shared establishes only that. It does not identify the second compound, measure how much is present, or show when it formed. Those require further work, usually LC-MS and a separation designed around the new impurity.
Battle Born posts an independent reverse-phase HPLC result on each product page. Like any single-method purity figure, it is most informative when read together with its chromatogram and understood as a measure of the species that method resolves.
Questions
Can co-elution make a peptide look less pure than it is?
Not through the area percentage calculation. Hidden impurity area is credited to the main peak, so the reported purity can only be too high.
Is diode-array peak purity enough to rule out co-elution?
Only for impurities whose UV spectra differ from the parent. Diastereomers and isoaspartate forms usually share the parent’s spectrum and will pass unnoticed.
Why might a better method report lower purity?
Better resolution separates impurities that another method hid under the main peak. The lower figure can be the more accurate one.
Can mass spectrometry detect every co-eluting impurity?
No. It distinguishes species by mass, so isomers with identical mass need an orthogonal separation instead.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.